Effect of Aspirin on Pre-eclampsia and Fetal Growth Restriction in Obese Pregnant Women: A Randomized Controlled Clinical Trial

Aim(s): Obesity in pregnant women is a serious health problem that has many complications such as pre-eclampsia and fetal growth restriction (FGR). The aim of the present study was to evaluate the effect of aspirin on prevalence of pre-eclampsia and FGR in obese pregnant women. Materials & Methods: This randomized controlled clinical trial was conducted on ۱۸۷ pregnant women referring to birth center of Mofatteh Clinic, Yasuj University of Medical Sciences, Yasuj, Iran in ۲۰۱۷-۲۰۱۸. The subjects were selected using purposive sampling method and randomly divided into two groups; intervention group (n=۸۹) and control group (n=۹۸). The intervention group received ۸۰mg/day aspirin and the control group received placebo at ۱۳-۲۰ weeks of gestation until ۳۴ weeks of pregnancy. Data were analyzed by SPSS ۲۱ software using Chi square test. Findings: The prevalence of pre-eclampsia (۱.۱ vs. ۱۱.۲) and FGR (۳.۴ vs. ۲۱.۴) were significantly lower in the intervention group compared to the control group (p<۰.۰۵). Conclusion: Administration of ۸۰mg/daily of aspirin from ۱۳-۲۰ weeks of gestation in obese pregnant women reduces the incidence of pre-eclampsia and FGR, which could support the positive role of aspirin in preventing pre-eclampsia and FGR.

Keywords:

aspirin , obesity , pregnancy , preeclampsia , fetal growth restriction